Hypertension Clinical Trial
Official title:
Ratio of Dietary Calcium to Magnesium on Cardiovascular Risk of High-risk Population: an Intervention Study
Although the epidemiological studies indicate how magnesium and calcium may interact to affect cardiovascular risk, current clinical trials have not elucidated the associations, particularly among hypertensive patients. To address the research gap, we have to examine how magnesium may influence cardiovascular profile of hypertensive patients via the modification of calcium homeostasis. Meanwhile, large-scale cohorts in China suggested keeping dietary calcium: magnesium ratio within 2.3 can reduce the risk of cardiovascular mortality. The results indicate the potential for individualized nutrition. This study will recruit uncontrolled hypertensive patients taking single drug and investigate whether calcium-magnesium combined supplements help to control their blood pressure. In standardized manner, subjects in the intervention group and the control group (each with 21 subjects) will be assessed for their dietary calcium and magnesium intake in the previous three months, so that researchers can provide calcium and/or magnesium supplements to maintain a calcium/magnesium ratio as 2.3. The effect of supplementation will be evaluated by the blood pressure changes in the 12th week of intervention.
In 2015, the prevalence of hypertension in Chinese adults was 25.2%, which can be translated
into 25 million people with hypertension in Guangdong Province. Hypertension is also related
to narrowing and occlusion of the cardiovascular vessels. In China, coronary heart disease
and stroke are the main causes of death in many provinces, and the early prevention of
cardiovascular disease risk in patients with hypertension has become a research direction
dedicated to the whole population. Magnesium is the second most abundant intracellular ion in
the body, which can regulate vascular tone, and together with calcium leads to changes in
vascular smooth muscle tone and contractility. Magnesium deficiency is associated with
oxidative stress, inflammation, endothelial dysfunction, platelet aggregation, insulin
resistance, and hyperglycemia; in the long run, dietary magnesium deficiency also increases
the risk of developing metabolic syndrome, type 2 diabetes, cardiovascular disease, and
cancer. However, the impact of nutrients on health is affected by different dietary factors.
Calcium and magnesium share different ion receptors or channels, including Calcium-sensing
receptor (modulates parathyroid hormone levels, thereby increasing the production of vitamin
D), as well as TRPM6 and TRPM7 (modulates the absorption of calcium and magnesium ions). In a
large meta-analysis, there is also evidence that calcium supplements may reduce blood
pressure in healthy people.
In addition, in epidemiological studies, we can see the interactive relationship between
calcium and magnesium. In the American population, when the ratio of calcium to magnesium is
<2.8, dietary intake of calcium and magnesium can reduce the risk of colorectal adenoma.
However, when the ratio of calcium to magnesium is too low (<2.0), it may also cause adverse
effects. According to data from more than 130,000 people in the Shanghai Women's Health Study
and the Shanghai Men's Health Study, the median calcium-magnesium ratio (1.7) in the Chinese
population is much lower than the calcium-magnesium ratio (3.0) in the US population. When
the calcium-magnesium ratio is > 1.7, calcium and magnesium intake can reduce the mortality
of cardiovascular disease; but when the calcium-magnesium ratio is <1.7, magnesium intake
increases the risk of cardiovascular death in women. Although the interaction between
magnesium and calcium can influence cardiovascular risk in epidemiological studies, the
current clinical evidence have not fully verified the relationship, especially among
hypertensive patients . To substantiate the research findings, it is necessary to explore how
calcium-magnesium intervention can improve the cardiovascular risk factors of hypertensive
patients. In addition, personalized nutrition intervention is also a research direction to be
explored. Unlike the unified dosage in the past, it may be more important to formulate
supplements according to individual dietary habits. In 2018, Vanderbilt University's team
conducted a clinical trial among 180 healthy adults with personalized magnesium supplements
and examined on the effects of blood vitamin D. They adjusted the dose of supplements
according to the calcium-magnesium ratio in the diet at baseline to achieve a
calcium-magnesium ratio of 2.3, and tested changes in various types of vitamin D in the
blood. They found that the effect of magnesium supplements on vitamin D levels varied
according to the baseline 25(OH)D concentration. When 25(OH)D levels are higher, magnesium
supplements reduced the levels of 25(OH)D3 and 24,25(OH)2D3. But when 25(OH)D is low,
magnesium supplements increased the level of 25(OH)D3. This is the first study to use
baseline dietary intakes for personalized nutrition interventions, but they have not explored
whether interventions can affect cardiovascular risk factors in hypertensive patients. More
randomized trials are needed to verify the efficacy of intervention, especially in high-risk
populations.
To answer the above questions, this study is a randomized trial to ensure that the highest
level of evidence is obtained and will recruit hypertensive patients in Guangdong Provincial
People's Hospital. The intervention and control group have the same number of people.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |